By Fineline Cube 
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with compatriot firm Qilu Pharmaceutical. The deal grants Qilu development, manufacturing, improvement, utilization, and commercialization rights to Mabwell’s Mailisheng (albipagrastim alfa) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.
Deal Structure
The agreement could be worth up to RMB 500 million (USD 70 million), including a non-refundable upfront payment of RMB 380 million (USD 53 million) and potential double-digit royalties based on product net sales.
Product Profile
Mailisheng is a recombinant human serum albumin-human granulocyte colony-stimulating factor (G-CSF) fusion protein. It is designed to reduce the incidence of febrile neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs. The product’s extended half-life, achieved through genetic fusion with human serum albumin, allows for less frequent dosing and improved patient compliance.
Technical Advantages
Produced using a Pichia pastoris expression system, Mailisheng offers simplified manufacturing without chemical modification, ensuring higher product homogeneity and favorable safety.-Fineline Info & Tech